Incyte 'downsizing' IDO1 program, ends some combo trials

Incyte Corp. (NASDAQ:INCY) reported 1Q18 earnings and said it is "downsizing" its program evaluating epacadostat, its indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. The company plans to halt enrollment of six pivotal trials of epacadostat in combination with anti-PD-1 mAbs Keytruda pembrolizumab from Merck & Co. Inc

Read the full 457 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE